MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's
Lymphoma
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that it
has dosed the first patient in a Phase 2 clinical trial of MOR208 in Non-
Hodgkin's Lymphoma (NHL). MOR208 is a potent Fc-optimized anti-CD19 antibody to
which MorphoSys gained worldwide rights via an exclusive license and
collaboration agreement with Xencor in 2010.
The open-label, multicenter, single-arm clinical trial is designed to assess the
efficacy of MOR208 in patients with relapsed or refractory Non-Hodgkin's
Lymphoma. Secondary outcome measures include response duration, safety and
pharmacokinetics of MOR208. A total of up to 120 patients are planned to be
enrolled in four separate sub-indications (FL, MCL, DLBCL and other forms of
indolent NHL). More information on the trial can be found by searching for
MOR208 at www.clinicaltrials.gov. The trial is to be conducted at sites across
both Europe and the US.
"In MOR208 we have a very exciting cancer program with a huge potential.
Evaluating MOR208 in NHL and B-ALL - building on the data we already have for
CLL - should enable us to assess the therapeutic benefit and broader commercial
potential of the molecule in hematological malignancies," commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG. "Broadening the drug's
development program into additional indications is intended to maximize the
value of this compound."
MOR208 showed encouraging signs of preliminary anti-tumor activity and an
acceptable safety and tolerability profile in a Phase 1/2a trial in patients
with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). In addition to the phase 2 trial in NHL, MorphoSys
is currently evaluating the compound in a phase 2 trial in B-cell Acute
Lymphoblastic Leukemia (B-ALL).
B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and
fifty thousand patients in the seven major markets each year. The target
molecule CD19 is expressed more broadly and earlier in B-cell development than
CD20, the target of the marketed cancer drug Rituxan(®). Therefore targeting
CD19 could potentially allow for an even broader therapeutic use of MOR208 than
marketed anti-CD20 antibodies.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1700850/561416.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1700850]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Uranerz announces First Quarter 2013 Financial ResultsDatum: 13.05.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 258957
Anzahl Zeichen: 5782
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 191 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
